Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 7/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | TK1 | P04183 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21758938 | 0.81 | XDH (0.36) | XDHPNPHPRT1MEN1KMT2A | |
| SCHEMBL3427614 | 0.79 | CDK1 (0.47) | HPGDXDHPNPMEN1KMT2A | |
| SCHEMBL24236963 | 0.76 | HPGD (0.46) | HPGDXDHPNPHPRT1MEN1 | |
| SCHEMBL23679502 | 0.76 | HPGD (0.46) | HPGDXDHPNPHPRT1MEN1 | |
| SCHEMBL22901682 | 0.75 | HPGD (0.43) | HPGDXDHPNPMEN1KMT2A | |
| SCHEMBL18520809 | 0.75 | CDK2 (0.46) | HPGDXDHHPRT1 | |
| SCHEMBL21943445 | 0.73 | HPGD (0.42) | HPGDXDHPNPHPRT1MEN1 | |
| SCHEMBL3424722 | 0.73 | PDE1A (0.55) | HPGDPNPHPRT1TK1 | |
| SCHEMBL22462003 | 0.73 | KDM4E (0.47) | HPGDMEN1KMT2ATSHRTK1 | |
| SCHEMBL24222086 | 0.73 | PNP (0.42) | HPGDPNPHPRT1TSHRHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | HPGD 1329/4885XDH 16/4885PNP 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.